palmoplantar erythrodysesthesia

palmoplantar erythrodysesthesia

hand-foot syndrome.
References in periodicals archive ?
The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or treatment of Palmoplantar Erythrodysesthesia Syndrome, PPES (caused for example by fluoropyrimidines-based chemotherapy) and of Hand-Foot Skin Reactions, HFSR (caused for example by multitargeted kinase inhibitors, MKIs).
About Palmoplantar Erythrodysesthesia Syndrome (PPES) / Hand-Foot Skin Reactions (HFSR)